Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28420730 | 1.00 | MEN1 (0.74) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1557185 | 0.98 | MEN1 (0.77) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2044134 | 0.91 | — | — | |
| SCHEMBL9259257 | 0.89 | MEN1 (0.94) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL11758762 | 0.89 | MEN1 (0.94) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL21765846 | 0.89 | MEN1 (0.94) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL17229157 | 0.86 | MEN1 (1.00) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL28422719 | 0.83 | CASP2 (0.74) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL1556878 | 0.83 | CASP2 (0.74) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL2944555 | 0.82 | MEN1 (0.81) | MEN1KMT2ACASP2NAAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-2308828-A2 | CaSR antagonist | Japan Tobacco Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| EP-2189439-A2 | CaSR antagonist | Japan Tobacco, Inc. (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-20090326058-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1619180-B1 | CaSR ANTAGONIST | JAPAN TOBACCO INC (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20080255042-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7285572-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20060135572-A1 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1630157-A1 | CaSR ANTAGONIST | JAPAN TOBACCO INC. (JP) | 2006-03-01 | — | — | EP | disclosed |
| EP-1619180-A1 | CaSR ANTAGONIST | JAPAN TOBACCO INC. (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | JAPAN TOBACCO INC. | 2005-02-10 | — | — | US | disclosed |
| US-5124331-A | Anticancer agents | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1992-06-23 | — | — | US | disclosed |
| EP-0364598-A1 | 3,4-dihydrothieno ¬2,3-d pyrimidine compounds and pharmaceutical application thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-04-25 | — | — | EP | disclosed |
| US-4786649-A | ANTISEPTICS | OTSUKA PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-11-22 | — | — | US | disclosed |
| EP-0228035-A2 | Antimicrobial 1-thienyl-4-oxoquinoline-3-carboxylix acid compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326058-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | MEN1 1040/4885KMT2A 3327/4885CASP2 1948/4885 |
| US-20060135572-A1 | CaSR antagonist | CASR, CALCR, CALCRL | MEN1 1669/4885KMT2A 3258/4885CASP2 2108/4885 |
| US-20120301552-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | MEN1 1040/4885KMT2A 3327/4885CASP2 1948/4885 |
| US-20080255042-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | MEN1 1040/4885KMT2A 3327/4885CASP2 1948/4885 |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | CASR, CALCR, GRK2 | MEN1 1836/4885KMT2A 2247/4885CASP2 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.